Massachusetts General Hospital Researchers and Prevencio Announce AI-driven HART® CVE Blood Test Accuracy for Patients with Coronary Chronic Total Occlusion

HART CVE test data presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting

KIRKLAND, Wash.--(BUSINESS WIRE)-- Prevencio, Inc., the AI-Powered Cardiac Blood Test Company, today announces the presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART^® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion (CTO).

Researchers from Massachusetts General Hospital (MGH) tested 241 patients with chronic total occlusion of at least one coronary (heart) artery for the risk of a major adverse cardiac event, including non-fatal myocardial infarction, stroke, and cardiovascular death through four years follow up. Using HART CVE risk scores, the high-risk patients were more than 12 times more likely to experience a myocardial infarction, stroke, or cardiovascular death as compared to low-risk patients.

Approximately 25% of patients with obstructive heart disease have Chronic Total Occlusion or total blockage of a coronary heart artery. Invasive management with coronary intervention, such as coronary stents, is most often dictated by symptoms, which is rather subjective.

“Surprisingly accurate risk stratification models to predict risk and longer-term clinical outcomes in coronary Chronic Total Occlusion patients prior to invasive treatment has not been studied,” said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Director of Biomarker Trials at the Baim Institute for Clinical Research, and Principal Investigator in development, validation, and ongoing testing of the HART tests. “HART CVE demonstrated robust accuracy for determining risk in these Chronic Total Occlusion patients. Having an objective, accurate, inexpensive, and accessible blood test, such as HART CVE, to judge the risk for non-fatal myocardial infarction, stroke and cardiovascular death may inform differences in need for intensity of medication, follow up frequency, and thresholds for conducting more expensive, invasive, and potentially more risky procedures, such as coronary stents.”

“The Chronic Total Occlusion patient population adds to a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, aortic disease, and peripheral artery disease, which HART CVE has demonstrated accuracy for cardiac risk assessment,” stated Rhonda Rhyne, Prevencio’s President and Chief Executive Officer. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed, and we are pleased to offer HART tests for patient care and clinical trials.”

Prevencio’s two lead tests, HART CVE and HART CADhs, are currently available for patients and clinical trials. HART CVE determines a patient’s one-to-four-year risk for a heart attack, stroke, or cardiovascular death, while HART CADhs assesses whether a patient has obstruction of the heart arteries and is at imminent risk of a heart attack.

For additional information, visit Prevencio, Inc.

About Prevencio HART Tests:

Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.

Our three lead tests include:

1. HART CVE^® – 1-year risk of heart attack, stroke, or cardiac death
2. HART CADhs^® – obstructive coronary artery disease diagnosis
3. HART KD^® – Kawasaki disease diagnosis

HART test results have been peer-reviewed published 33 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; Pediatric Academic Societies International Sessions; International Spinal Cord Society Scientific Sessions; ASTRO Scientific Sessions; Transcatheter Cardiovascular Therapeutics Sessions; and International Kawasaki Disease Symposium) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Open Heart; Biomarkers in Medicine; Journal of American Heart Association; European Journal of Preventive Cardiology; and International Journal of Cardiology).

About Prevencio, Inc.:

Prevencio’s value proposition is “Power of AI to Prevent the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.

Forward-Looking (Safe Harbor) Statement:

Except for historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231024769637/en/